Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Capital Expenditures (2019 - 2025)

Biodesix's Capital Expenditures history spans 7 years, with the latest figure at $86000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 89.75% year-over-year to $86000.0; the TTM value through Dec 2025 reached $259000.0, down 91.98%, while the annual FY2025 figure was $259000.0, 91.98% down from the prior year.
  • Capital Expenditures reached $86000.0 in Q4 2025 per BDSX's latest filing, up from $48000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.7 million in Q1 2023 to a low of $48000.0 in Q3 2025.
  • Average Capital Expenditures over 5 years is $1.6 million, with a median of $498000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 2829.77% in 2023, then tumbled 97.35% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $530000.0 in 2021, then soared by 264.15% to $1.9 million in 2022, then surged by 54.61% to $3.0 million in 2023, then plummeted by 71.88% to $839000.0 in 2024, then tumbled by 89.75% to $86000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Capital Expenditures are $86000.0 (Q4 2025), $48000.0 (Q3 2025), and $51000.0 (Q2 2025).